Navigation Links
Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease
Date:3/2/2009

e bodies, naturally occurring compounds produced by the body at low levels. These ketone bodies act as a secondary energy source for the brain to help maintain and improve cognitive function.

"It's a novel and effective approach to Alzheimer's disease," said Steve Orndorff, Ph.D., founder and CEO, Accera, Inc. "Similar to how insulin helps diabetics, Axona supplements energy for the brain so that neurons can continue to function properly and patients can maintain cognition. As a company focused on developing new therapies for central nervous system disorders, we're very excited about Axona's potential to help the AD community."

Axona was evaluated in a double-blind, randomized, placebo-controlled study performed at multiple U.S. clinical centers in a population of 152 patients with probable mild-to-moderate Alzheimer's disease. Patients taking Axona demonstrated significant improvements in cognitive function by day 45 (as measured by the Alzheimer's Disease Assessment Scale-Cognitive subscale or ADAS-Cog score). These patients also maintained a slight improvement from baseline after 90 days of daily Axona administration, whereas the placebo group demonstrated a decline. In these trials Axona was demonstrated to be safe, effective and generally well-tolerated.

Axona is supplied as a powder formulation in individual packets. Contents should be mixed with water and consumed at breakfast. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's therapies.

About Alzheimer's Disease

AD, the most common form of dementia, is a progressive and fatal disease for which there is no cure. It attacks the brain's nerve cells, resulting in loss of memory, executive function, thinking and language skills. According to recent data, every 71 seconds someone in America develops AD.

In the U.S., 5.2 million people are living with AD, an
'/>"/>

SOURCE Accera
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
3. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
4. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
5. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
8. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
9. Video: Keppra XR(TM) Approved in the U.S.
10. Video: Fortune 1000 Executives: New President Must Fix Education Gap
11. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... SPRING, Md. , Dec. 24, 2014  United Therapeutics ... Medtronic, Inc. (NYSE: MDT ) has submitted ... Drug Administration (FDA) for the use of Medtronic,s SynchroMed ... newly developed catheter) for use with United Therapeutics, Remodulin ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... HGS product sales achieved with delivery of ABthrax(TM) to U.S. ... cash balance of $397 million as of March 31, up ... for second Phase 3 trial of Albuferon (R) ... fall 2009 - - Initiation of Syncria (R) ...
... RICHMOND, Calif., April 29 Sangamo BioSciences, Inc. ... success of its zinc finger DNA-binding protein (ZFP) ... Nature by licensing partner Dow AgroSciences ... technology for the efficient generation of maize plants ...
... , ... Austin, Texas (PRWEB) April 29, 2009 -- ... storing and distributing content, today announced the release of CAStor 3.0, ... virtual CAStor nodes in a single, physical server chassis. CAStor Cluster ...
Cached Biology Technology:Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 2Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 3Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 4Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 5Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 6Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 7Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 8Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 9Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments 10Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 2Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 3Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species 4Caringo Delivers Storage Cluster in a Box with CAStor 3.0 2
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest Baptist ... building for its School of Medicine. Funding for this $50 ... that will be publicly launched next summer. ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... flu viruses that infect birds and humans, a discovery that ... and aid in the development of vaccines against a deadly ... to infect humans depends on whether it can bind to ... respiratory cells. Now that we know what to look ...
... Diego has become the first campus on the West Coast ... voluntary, legally binding trading system to reduce emissions of greenhouse ... the nation to join the climate exchange. Joining the ... conserve energy and reduce greenhouse gases (GHG). Trading in GHG ...
... Ohio State University will battle for the BCS National ... but if the game was held in the Louisiana ... Louisianas wetlands are being lost at the rate of ... against this rapid destruction, the two universities joined forces ...
Cached Biology News:MIT finds key to avian flu in humans 2MIT finds key to avian flu in humans 3UC San Diego begins trading greenhouse gas credits on Chicago Climate Exchange 2LSU and Ohio State battle on football field, collaborate in research field 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Request Info...
Homo sapiens olfactomedin 1, transcript variant 3...
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
Biology Products: